Milestone For UK’s NICE As Wound Healing Device Trial It Recommended Is Due To Start

In short

UK’s National Institute for Health and Clinical Excellence (NICE) is the independent organisation responsible for providing national guidance and standards on the promotion of good health and the prevention and treatment of ill health.

The first clinical trial resulting from NICE medical technology guidance recommendations is due to start soon on the MIST therapy system. MIST, developed by U.S. company Celleration Inc., is thought to promote chronic wound healing, a claim which will be challenged clinically when the system is compared against standard of care, following the organisations strong encouragement of further research.


The MIST Therapy system claims to promote wound healing in chronic, ‘hard to heal’ and acute wounds by delivering low-energy, low-intensity ultrasound to the base of the wound through a continuous saline mist. The mist acts as a channel for transmitting ultrasonic energy to the base of the wound, which aims to promote wound healing by stimulating tissue regeneration and removing dead tissue and bacteria. It is claimed by the device manufacturer that it can improve healing rates, thus reducing treatment time and associated costs, and so offers advantages to both patients and the NHS. The trial objective is to determine if there is a difference in the mean change in wound area after 8 weeks of treatment, between patients treated with MIST plus standard care, and those receiving standard care alone.

NICE’s Medical Technologies Advisory Committee (MTAC) looks at whether a device offers benefits to the patient and the NHS at a lower cost compared with similar products, or increased benefits for equal cost. MTAC’s view was that the MIST device showed promise, but there was not yet enough evidence of sufficient quality to enable a recommendation for routine adoption of its use.

The forthcoming clinical trial is the first significant output of the capacity that NICE has put in place for facilitating the development of further evidence, stemming from recommendations by NICE medical devices and diagnostics advisory bodies. The trial on the MIST Therapy system will recruit 40 patients with chronic venous leg ulcers, and will be undertaken independently by Cardiff University and Cardiff and Vale University Health Board.

In addition to the research recommendation, MTAC also advised that current users of the MIST Therapy system who are unable to join research studies should use NICE’s audit criteria to collect further information on healing rates, duration of treatment and quality of life and publish their results. NICE plans to review the 2011 guidance when new and substantive evidence becomes available.

NICE comments

Professor Carole Longson, Director of the NICE Centre for Health Technology Evaluation, said: “It’s excellent news that new clinical trials are due to start on the use of MIST Therapy system, in line with the research recommended by the Medical Technologies Advisory Committee. The Committee thought that the MIST system showed real promise, but there simply wasn’t the quantity and quality of evidence needed to support the case for adoption at that point. While this further research is undertaken, it’s important to stress that more data can be generated and collected by all who use the device, to help inform further considerations on its clinical utility. As set out in the recommendations, NICE will review this guidance when new and substantive evidence becomes available. We hope that for manufacturers, this new research milestone will highlight further potential benefits of notifying their device to the NICE Medical Technologies Evaluation Programme.”

Investigator comments

Professor Keith G Harding, Chief Investigator, Wound Healing Research Unit, Cardiff University said: “We’re delighted to have received the go-ahead to start the trial on MIST, the medical device which may improve wound healing in hard-to-heal ulcers. There is a small amount of evidence to suggest that ulcers treated with MIST will heal more quickly than those having usual treatment; this trial will enable us to generate more independent evidence to show if this is actually the case. The results will then help NICE when it comes to review the original guidance, in deciding whether patients with chronic wounds would benefit from being treated using MIST.”

Source: NICE